Introduction: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S. In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first-and third-generation EGFR tyrosine kinase inhibitors. However, this has not been reported clinically.
Introduction
The paradigm for the pharmacological management of advanced NSCLC has been revolutionized by the development of EGFR tyrosine kinase inhibitors (TKIs). Although most patients harboring EGFR activating mutations respond to such treatments, the responses are often not permanent, with an approximate median progression-free survival (PFS) of 1 year. 1 Numerous resistance mechanisms have been elucidated, with EGFR T790M being the most commonly acquired resistance mutation and accounting for 50% of resistance cases. 2, 3 Several mutant-selective irreversible inhibitors have been developed to target tumors harboring EGFR T790M. Osimertinib, a third-generation EGFR TKI, has demonstrated significant efficacy against tumors bearing EGFR T790M and has been approved for patients with EGFR T790M-positive NSCLC after progression during prior EGFR TKI therapy. 4 The efficacy of osimertinib was compromised by the development of EGFR C797S, which is responsible for 30% of cases of resistance. 5 In vitro studies have shown that if EGFR C797S and T790M mutations exist in trans, cells are resistant to *Corresponding author.
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third-generation EGFR TKIs but remain sensitive to a combination of first-and third-generation EGFR TKIs. 5 Here, we report the first clinical evidence of efficacy generated by a combination of first-and third-generation EGFR TKIs targeting concomitant EGFR T790M and C797S in trans.
Materials and Methods

Patient Information
This patient was treated and evaluated at our institute. This study was approved by the institutional review board at the Guangdong General Hospital. The patient provided informed consent to this study and gave permission for the use of peripheral blood and tumor tissues.
Tissue DNA Extraction
A lung tumor sample was obtained by core biopsy during the initial diagnostic procedure. Supraclavicular lymph node was resected at progressive disease (PD) after afatinib. Genomic DNA was extracted from paraffinembedded slides by using an E.Z.N.A Tissue DNA Kit (Omega Biotek, Doraville, GA) according to the manufacturer's protocol.
Mutation Analysis
Mutations in EGFR exons 18 through 21 were examined with a DxS EGFR Mutation Test Kit (Amoy Diagnostics, Xiamen, People's Republic of China). KRAS mutation was analyzed by Sanger sequencing as described. 6 ALK receptor tyrosine kinase gene (ALK) rearrangement was detected by fluorescence in situ hybridization using the Vysis LSI ALK Break-Apart FISH Probe (Abbott Molecular, Des Plaines, IL) according to the manufacturer's instructions.
Preparation of Plasma Cell-Free DNA Cell-free DNA was extracted as described. 7 In brief, 10 mL of whole blood was collected and cell-free DNA was extracted from plasma samples by using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Next-Generation Sequencing Library Preparation
Library preparation was performed as described. 7 Fragments with a size of 200 to 400 base pairs were selected and followed by hybridization with capture probes baits, hybrid selection with magnetic beads, and polymerase chain reaction (PCR) amplification. Indexed samples were sequenced on a Nextseq500 sequencer (Illumina, Inc., San Diego, CA) with paired-end reads.
Sequencing Data Analysis
The sequencing data in the FASTQ format were mapped to the human genome (hg19) with BurrowsWheeler Aligner aligner 0.7.10. Local alignment optimization, variant calling, and annotation were performed by using GATK 3.2, MuTect, and VarScan, respectively. DNA translocation analysis was performed with both Tophat2 and Factera 1.4.3.
Results
A 43-year-old man with no history of smoking presented with persistent dry cough for more than 2 months. Positron emission tomography-computed tomography (CT) revealed a fludeoxyglucose F 18-positive lesion in the peripheral right lower lung lobe and metastases in the right hilar lymph node and brain, with no symptoms of brain metastasis. CT-guided core needle biopsy of the lung revealed adenocarcinoma with EGFR exon 19 deletion (19del) by using amplification refractory mutation system-PCR with no other concurrent driver mutations. The patient was enrolled in a clinical trial of afatinib (BIBW 2992) for patients with advanced NSCLC with EGFR mutation (NCT01953913). He was treated with afatinib, 40 mg daily, and achieved a partial response (PR) according to the Response Evaluation Criteria in Solid Tumors 1.1 at 1 month after initiation of treatment. He experienced PD after a PFS of 12.8 months.
At disease progression, his CT scan revealed an increase in both the size and number of pulmonary lesions, accompanied by involvement of the supraclavicular lymph node, which was excised under the consent of the patient. Repeat tissue biopsy revealed an acquired EGFR T790M in conjunction with the original EGFR sensitizing mutation by using amplification refractory mutation system-PCR. Subsequently, the patient was treated with osimertinib, 80 mg once daily, and achieved a PR. After a PFS of 7.4 months, multiple new metastatic peritoneal lymph nodes developed and were accompanied by deteriorating performance status. Because of the infeasibility of obtaining additional tissue biopsy specimens, liquid biopsy assessing circulating tumor DNA coupled with capture-based targeted sequencing was performed and revealed EGFR 19del (allelic fraction [AF] ¼ 3.49%) and EGFR C797S (AF ¼ 2.57%), which was located in trans with T790M (AF ¼ 2.84%) (Fig. 1A) . A combinatorial treatment consisting of erlotinib and osimertinib was administered. The patient experienced significant improvement in abdominal pain, jaundice, fatigue, and malaise within 1 week and achieved a PR 1 month later with undetectable EGFR C797S (Fig. 1B) . PR was confirmed at 2 months after initiation of the treatment, with undetectable EGFR T790M and C797S, whereas EGFR exon 19del remained detectable throughout the treatment. He returned to the clinic on account of mild malaise and dyspnea, and his CT scan showed an enlarged pulmonary lesion and an increase in pleural effusion, resulting in PD with a PFS of 3 months (Fig. 2) . Liquid biopsy revealed the reappearance of EGFR C797S in conjunction with T790M and EGFR 19del. Interestingly, this time, EGFR C797S was located in cis to T790M (Fig. 1C) . The combinatorial treatment was suspended and avitinib, a third-generation EGFR TKI, was administered for 1 week. However, no clinical benefit was observed; instead, the patient presented with increasing pleural effusion, fatigue, jaundice, and abdominal pain, with a performance status of 2. Systemic chemotherapy, which included paclitaxel and bevacizumab, was given and resulted in significant improvement of the patient's clinical symptoms.
We had previously collected the patient's peripheral blood at various treatment milestones during afatinib treatment, and we performed capture-based targeted sequencing retrospectively. The sequencing results from the circulating tumor DNA were in agreement with the tissue biopsy results. The dynamic changes in AF of EGFR mutations are illustrated in Figure 3 , and the overall clonal progression is shown in Figure 4 .
Discussion
EGFR C797S, disrupting the covalent binding between the cysteine residue at position 797 of EGFR and third-generation EGFR TKIs, is a well-established resistance mechanism. 8 Previous studies have shown that first-generation EGFR TKIs exert their efficacy independent of the cysteine at position 797. 9 Furthermore, another in vitro study revealed that a combination of first-and third-generation EGFR TKIs can restore EGFR inhibition when T790M and C797S exist in trans.
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In this case, we performed capture-based targeted ultradeep sequencing on longitudinal plasma samples obtained at various milestones in the treatment of a patient with advanced NSCLC who was undergoing targeted therapy. At disease progression after administration of osimertinib as a single agent, our sequencing data revealed the coexistence of three mutations, T790M, C797S, and EGFR 19 del. EGFR T790M and C797S were located in trans, a rarely reported configuration that was observed in one participant in the phase I AURA study. 4 This is the first in trans case in our cancer center. The in trans EGFR C797S became undetectable after response to administration of a combination of first-and thirdgeneration EGFR TKIs, confirming the target of the combinatorial treatment. Interestingly, at disease progression, in trans EGFR C797S remained undetectable and C797S located in cis (AF ¼ 0.53%) to T790M (AF ¼ 0.89%) emerged, exerted resistance to the combinatorial treatment, and potentially dominated the disease progression, while EGFR 19del remained present (AF ¼ 0.79%).
It is noteworthy that C797S in trans with T790M responded to the combination of erlotinib and osimertinib in a short interval and that the lesion in thoracic activity progressed more rapidly than in the abdomen. We tend to believe that clonal heterogeneity plays an important role and double resistant mechanisms of in trans and in cis against osimertinib exist simultaneously. The clone of C797S in cis with T790M seems more aggressive than C797S in trans with T790M because it grows in such a short period.
To the best of our knowledge, we have reported the first clinical evidence of efficacy generated by combination therapy of first-and third-generation EGFR TKIs targeting concomitant EGFR T790M and C797S in trans. Furthermore, we have also revealed for the first time that an acquired in cis EGFR C797S can emerge after exposure to combinatorial treatment and potentially mediate resistance. A recent publication delineating the efficacy of brigatinib (an anaplastic lymphoma kinase TKI under clinical development) against triple-mutant EGFR-positive cells sheds some light on potential treatment options for this patient. 10 
